Resverlogix Corp. President & CEO Invited to Speak on CNBC's Morning Call.

CALGARY, Alberta -- Donald McCaffrey, President and CEO of Resverlogix Corp. (TSX:RVX), will appear as a guest speaker on CNBC's Morning Call. Morning Call is a leading global business news program airing Monday through Friday from 10:00 a.m. to 12:00 p.m. EST on CNBC. Mr. McCaffrey will be addressing the company's lead technology program NEXVAS(TM), and its potential promise in the largest pharmaceutical market segment Cardiovascular Disease. The interview will take place this morning at 11:45 a.m. EST on Tuesday February 22nd.

"It is a privilege for Resverlogix to be on CNBC and share our insights on the exciting new area of HDL enhancing compounds and the potential they hold for future cardiovascular medicine," stated Donald McCaffrey. "This is a very exciting time for the biotechnology and life sciences industry especially as HDL enhancement technologies have shown the ability to actually reduce atherosclerotic plaque, one of the major causes of coronary heart disease."

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology program NEXVAS(TM) applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The corporation's second technology program TGF-Beta Shield(TM) utilizes an adoptive immunotherapy  approach to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet medical need. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not except responsibility for the adequacy or accuracy of this news release.

Resverlogix Corp. (TSX:RVX)